Normativa europea / Area HIV
Updated Feb. 17, 2022 - Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
![Immagine News](/media/cnyhiizm/cat-4.jpg?anchor=center&mode=crop&width=722&height=442)
What’s New
February 17, 2022
Key updates to the guidelines include the following:
Mycobacterium tuberculosis
- Updated references and rationales.
- Updated drug–drug interactions.
- Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy.
- Clarified that, for the treatment of drug-resistant tuberculosis, it is possible to use drug regimens with total duration as short as 6 to 12 months total when bedaquiline is part of the regimen instead of the 18 to 20 months total duration suggested by other sources
Link to the document: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines
Grazie per il tuo feedback!